Who and when should we screen for prostate cancer? Interviews with key opinion leaders

Sigrid Carlsson; Michael Leapman; Peter Carroll; Fritz H Schroder; Peter Albertsen; Dragan Ilic; Michael J Barry; Dominick Frosch; Andrew Vickers

doi:10.1186/s12916-015-0526-x

Who and when should we screen for prostate cancer? Interviews with key opinion leaders

Sigrid Carlsson, Michael Leapman , Peter Carroll, Fritz H Schroder, Peter Albertsen, Dragan Ilic, Michael J Barry, Dominick Frosch, Andrew Vickers

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Article › Other › peer-review

9 Citations (Scopus)

Abstract

Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own personal opinions on PSA screening.

Original language	English
Article number	288
Journal	BMC Medicine
Volume	13
DOIs	https://doi.org/10.1186/s12916-015-0526-x
Publication status	Published - 27 Nov 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12916-015-0526-x

23377257-oaFinal published version, 2.75 MB

Cite this

@article{4a71862c21bc4c69abe58a413667341f,

title = "Who and when should we screen for prostate cancer? Interviews with key opinion leaders",

abstract = "Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine{\textquoteright}s {\textquoteleft}Spotlight on Prostate Cancer{\textquoteright} article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world{\textquoteright}s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts{\textquoteright} views and give their own personal opinions on PSA screening.",

author = "Sigrid Carlsson and Michael Leapman and Peter Carroll and Schroder, {Fritz H} and Peter Albertsen and Dragan Ilic and Barry, {Michael J} and Dominick Frosch and Andrew Vickers",

year = "2015",

month = nov,

day = "27",

doi = "10.1186/s12916-015-0526-x",

language = "English",

volume = "13",

journal = "BMC Medicine",

issn = "1741-7015",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Who and when should we screen for prostate cancer? Interviews with key opinion leaders

AU - Carlsson, Sigrid

AU - Leapman , Michael

AU - Carroll, Peter

AU - Schroder, Fritz H

AU - Albertsen, Peter

AU - Ilic, Dragan

AU - Barry, Michael J

AU - Frosch, Dominick

AU - Vickers, Andrew

PY - 2015/11/27

Y1 - 2015/11/27

N2 - Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own personal opinions on PSA screening.

AB - Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own personal opinions on PSA screening.

U2 - 10.1186/s12916-015-0526-x

DO - 10.1186/s12916-015-0526-x

M3 - Article

SN - 1741-7015

VL - 13

JO - BMC Medicine

JF - BMC Medicine

M1 - 288

ER -